Gastroesophageal Junction Adenocarcinoma
Showing NaN - NaN of 9
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma Trial in China (Capecitabine, oxaliplatin, Disitamab Vedotin)
Not yet recruiting
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
- Capecitabine
- +3 more
-
Beijing, Beijing, China
- +10 more
Nov 23, 2023
Gastroesophageal Junction Adenocarcinoma Trial in Beijing (Serplulimab)
Recruiting
- Gastroesophageal Junction Adenocarcinoma
-
Beijing, ChinaPeking Union Medical College Hospital
Jun 15, 2023
Stomach Tumors, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma Trial in China (Atezolizumab, Tiragolumab, Oxaliplatin)
Active, not recruiting
- Stomach Neoplasms
- +2 more
- Atezolizumab
- +3 more
-
Beijing, China
- +10 more
Dec 21, 2022
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma Trial in Beijing (CS1001 mAb, CS1001 , Oxaliplatin)
Active, not recruiting
- Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- CS1001 monoclonal antibody
- +3 more
-
Beijing, ChinaBeijing Cancer Hospital
Sep 27, 2022
Gastric Tumors, Gastroesophageal Junction Adenocarcinoma Trial in Worldwide (Pembrolizumab, Paclitaxel)
Terminated
- Gastric Neoplasms
- Gastroesophageal Junction Adenocarcinoma
- Pembrolizumab
- Paclitaxel
-
Beijing, Beijing, China
- +35 more
Apr 1, 2022
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma Trial in China (Atezolizumab, Trastuzumab, Capecitabine)
Recruiting
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
- Atezolizumab
- +3 more
-
Beijing, China
- +9 more
Mar 11, 2022
Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma Trial in China (CT041 autologous CAR T-cell
Recruiting
- Gastric Adenocarcinoma
- +2 more
- CT041 autologous CAR T-cell injection
- Physician's Choice(Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody)
-
Hefei, Anhui, China
- +9 more
Feb 13, 2022
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma Trial in Beijing (Raltitrexed, Paclitaxel)
Completed
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
-
Beijing, ChinaChinese Academy of Medical Sciences
Jan 29, 2021
Gastric Adenocarcinoma, Advanced Solid Tumors, Gastroesophageal Junction Adenocarcinoma Trial in Beijing (AK104, Oxaliplatin,
Unknown status
- Gastric Adenocarcinoma
- +2 more
- AK104
- +2 more
-
Beijing, Beijing, ChinaBeijing Cancer Hospital
Feb 22, 2019